CD1D and myeloid sarcoma: There was no significant difference between the % of CD1d+/Iba1+ cells in healthy control tissue and NAWM (5.46 ± 12.20% and 1.82 ± 4.07%), nor were there increases in any type of lesion tissue obtained from MS patients (active at 7.52 ± 9.74%, chronic‐active lesion center at 3.09 ± 3.39% or chronic active lesion edge at 4.87 ± 4.68%).